Current FAP-targeting small molecules have shown to be successful for imaging with promising tumor-to-background ratios on PET/CT scans in various solid tumors (Kratochwil et al. 2019); however, their limited tumor retention time makes these molecules suboptimal for radionuclide therapy. Here, FAP is linked to neoplasm.